Indeed Noch et al., using data from the Phase 2 study evaluating buparlisib in patients with recurrent GBM (NCT05183204) show that buparlisib activation of insulin signaling promoting hyperglycemia were independently associated with poor prognosis [29]. The gene discussed is INS; the disease is Hyperglycemia.